Vietnam Medicinal Materials JSC (HSTC:DVM) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTC:DVM Vietnam Medicinal Materials JSC HSTC:DVM
32 GF Score
Price ₫4,600.00
! 1 Warning Sign
View Full Analysis

What is Vietnam Medicinal Materials JSC Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vietnam Medicinal Materials JSC's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₫469,405 Mil. Vietnam Medicinal Materials JSC's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₫11,197 Mil. Vietnam Medicinal Materials JSC's annualized EBITDA for the quarter that ended in Jun. 2026 was ₫72,377 Mil. Vietnam Medicinal Materials JSC's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 6.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vietnam Medicinal Materials JSC's Debt-to-EBITDA or its related term are showing as below:

HSTC:DVM's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.64
* Ranked among companies with meaningful Debt-to-EBITDA only.

Vietnam Medicinal Materials JSC  (HSTC:DVM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Vietnam Medicinal Materials JSC Debt-to-EBITDA Related Terms


Vietnam Medicinal Materials JSC Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Vietnam Medicinal Materials JSC's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vietnam Medicinal Materials JSC Debt-to-EBITDA Chart

Vietnam Medicinal Materials JSC Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
- - - - -

Vietnam Medicinal Materials JSC Quarterly Data
Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

HSTC:DVM vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vietnam Medicinal Materials JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vietnam Medicinal Materials JSC Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vietnam Medicinal Materials JSC's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vietnam Medicinal Materials JSC's Debt-to-EBITDA falls into.


HSTC:DVM
32GF Score
Vietnam Medicinal Materials JSC HSTC:DVM
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vietnam Medicinal Materials JSC Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vietnam Medicinal Materials JSC's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(540398.04499 + 13240.744126) / 113862.885036
=4.86

Vietnam Medicinal Materials JSC's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(469405.477162 + 11197.334679) / 72376.637452
=6.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.


Vietnam Medicinal Materials JSC Business Description

Address Zone 8, Phu Ninh Commune, Phu Ninh District, Phu Tho Province, Phu Ninh, VNM
Vietnam Medicinal Materials JSC is a company specializing in clean medicinal herbs and is committed to pharmaceuticals and health food products derived from natural medicinal herbs, with product quality as a top priority. Its business areas are the production and wholesale of medicinal herbs. Its activities include manufacturing and trading of pharmaceuticals, cultivation and processing of medicinal herbs, dietary supplements, wholesale and retail of medical products, cosmetics and equipment, and import and export of goods traded by the company. Its products are developed from standardized medicinal herbs under controlled cultivation, harvesting and processing, combining traditional remedies with science under strict quality control.
32GF Score

Get the complete analysis for HSTC:DVM

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫4,600.00
Price